IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0204681.html
   My bibliography  Save this article

Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life

Author

Listed:
  • Fernando Gracia
  • Mario Larreategui
  • Gaudencio Rodríguez
  • Aaron Benzadón
  • Michelle Ortiz
  • Divian Morales
  • Claudia Domínguez
  • Rosa Enith Carrillo
  • Carlos Valderrama
  • Luís Lizán
  • Blas Armién

Abstract

The purpose of this work is to estimate the costs associated with managing patients with MS in Panama and evaluating the impact of the disease on their health-related quality of life (HRQoL). Multicentric observational, retrospective, cross-sectional study. The costs were estimated from societal and patient perspectives and expressed in USD, 2015. The focus of the study is based on prevalence and on a “bottom-up” approach. To estimate the total cost per patient, annual reported use for each resource was multiplied by its unit cost. To evaluate HRQoL, patients completed the EQ-5D-3L questionnaire. 108 patients took part in the study. 82.41% were women with 44.78 (SD: 12.27) years. 61.11% presented mild (EDSS = 0–3.5), 25.93% moderate (EDSS = 3.5–6) and 12.96%, severe disability (EDSS≥6.5). The mean annual cost from the patient’s perspective was estimated at 777.99 USD (SD: 1,741.45) per patient. The mean cost from a societal perspective was estimated at 23,803.21 USD (SD: 13,331.83) per patient. Disease-modifying therapies (DMT) accounted for the main component of the cost. A deterioration in HRQoL was observed as the disease advances and as disability increases, with mobility and usual activities being the areas most affected by its progression. From both perspective, the cost per MS patient in Panama is high. In addition to the high economic impact, MS also exerts a negative impact on patient HRQoL, which increases as the disease advances.

Suggested Citation

  • Fernando Gracia & Mario Larreategui & Gaudencio Rodríguez & Aaron Benzadón & Michelle Ortiz & Divian Morales & Claudia Domínguez & Rosa Enith Carrillo & Carlos Valderrama & Luís Lizán & Blas Armién, 2018. "Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    • Handle: RePEc:plo:pone00:0204681
    DOI: 10.1371/journal.pone.0204681
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0204681
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0204681&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0204681?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Tarricone, Rosanna, 2006. "Cost-of-illness analysis: What room in health economics?," Health Policy, Elsevier, vol. 77(1), pages 51-63, June.
    2. Gisela Kobelt, 2006. "Costs and quality of life for patients with multiple sclerosis in Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 24-33, July.
    3. Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz, 2006. "Costs and quality of life of multiple sclerosis in Switzerland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 86-95, July.
    4. Olivia Ernstsson & Hanna Gyllensten & Kristina Alexanderson & Petter Tinghög & Emilie Friberg & Anders Norlund, 2016. "Cost of Illness of Multiple Sclerosis - A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-25, July.
    5. Gisela Kobelt, 2006. "Costs and quality of life for patients with multiple sclerosis in Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 24-33, July.
    6. Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz, 2006. "Costs and quality of life of multiple sclerosis in Switzerland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 86-95, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Olivia Ernstsson & Hanna Gyllensten & Kristina Alexanderson & Petter Tinghög & Emilie Friberg & Anders Norlund, 2016. "Cost of Illness of Multiple Sclerosis - A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-25, July.
    2. A. J. Hawton & C. Green, 2016. "Multiple sclerosis: relapses, resource use, and costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(7), pages 875-884, September.
    3. Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög, 2018. "Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 435-446, April.
    4. Oliver Findling & Magdalena Baltisberger & Simon Jung & Christian P Kamm & Heinrich P Mattle & Johann Sellner, 2015. "Variables Related to Working Capability among Swiss Patients with Multiple Sclerosis—A Cohort Study," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-9, April.
    5. Visintin, Erica & Tinelli, Michela & Kanavos, Panos, 2019. "Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries," Health Policy, Elsevier, vol. 123(2), pages 118-129.
    6. B. Svendsen & N. Grytten & L. Bø & H. Aarseth & T. Smedal & K-M. Myhr, 2018. "The economic impact of multiple sclerosis to the patients and their families in Norway," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1243-1257, December.
    7. Andrius Kavaliunas & Michael Wiberg & Petter Tinghög & Anna Glaser & Hanna Gyllensten & Kristina Alexanderson & Jan Hillert, 2015. "Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-11, December.
    8. Hanne Marie Bøe Lunde & Wenche Telstad & Nina Grytten & Lars Kyte & Jan Aarseth & Kjell-Morten Myhr & Lars Bø, 2014. "Employment among Patients with Multiple Sclerosis-A Population Study," PLOS ONE, Public Library of Science, vol. 9(7), pages 1-7, July.
    9. Massimiliano Agovino & Maria Ferrara, 2022. "Disabilit?: diseguaglianza sociale ed economica. Un?analisi empirica e teorica," ECONOMIA PUBBLICA, FrancoAngeli Editore, vol. 2022(1), pages 11-42.
    10. Roxanne Cooksey & Muhammad J Husain & Sinead Brophy & Helen Davies & Muhammad A Rahman & Mark D Atkinson & Ceri J Phillips & Stefan Siebert, 2015. "The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-17, July.
    11. Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi, 2019. "Cost-of-illness studies in nine Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 155-172, June.
    12. Paolo Angelo Cortesi & Ippazio Cosimo Antonazzo & Claudio Gasperini & Mihaela Nica & Daniela Ritrovato & Lorenzo Giovanni Mantovani, 2022. "Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy," PLOS ONE, Public Library of Science, vol. 17(3), pages 1-12, March.
    13. Joanna M Charles & Deirdre M Harrington & Melanie J Davies & Charlotte L Edwardson & Trish Gorely & Danielle H Bodicoat & Kamlesh Khunti & Lauren B Sherar & Thomas Yates & Rhiannon Tudor Edwards, 2019. "Micro-costing and a cost-consequence analysis of the ‘Girls Active’ programme: A cluster randomised controlled trial," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-17, August.
    14. Chien-Yuan Sher & Ho Ting Wong & Yu-Chun Lin, 2020. "The Impact of Dengue on Economic Growth: The Case of Southern Taiwan," IJERPH, MDPI, vol. 17(3), pages 1-12, January.
    15. Karine Chevreul & Coralie Gandré & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schiep, 2016. "Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 43-52, April.
    16. Jamison Pike & Scott D. Grosse, 2018. "Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 765-778, December.
    17. Hazo, Jean-Baptiste & Gandré, Coralie & Leboyer, Marion & Obradors-Tarragó, Carla & Belli, Stefano & McDaid, David & Park, A-La & Maliandi, Maria Victoria & Wahlbeck, Kristian & Wykes, Til & van Os, J, 2017. "National funding for mental health research in Finland, France, Spain and the United Kingdom," LSE Research Online Documents on Economics 82339, London School of Economics and Political Science, LSE Library.
    18. Susanne Mayer & Jonah Spickschen & K Viktoria Stein & Richard Crevenna & Thomas E Dorner & Judit Simon, 2019. "The societal costs of chronic pain and its determinants: The case of Austria," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-18, March.
    19. Lan Gao & Hao Hu & Fei-Li Zhao & Shu-Chuen Li, 2016. "Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-17, January.
    20. Bugge, Christoffer & Sæther, Erik Magnus & Brustugun, Odd Terje & Kristiansen, Ivar Sønbø, 2021. "Societal cost of cancer in Norway –Results of taking a broader cost perspective," Health Policy, Elsevier, vol. 125(8), pages 1100-1107.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0204681. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.